8月27日，药明生物盘中下跌3.05%，报49.2港元，成交额10.37亿港元。消息面上，公司此前于8月25日发布强劲中期业绩并上调全年指引，股价连续两日大涨（8月25日涨7.41%、8月26日涨4.02%），短期累积涨幅较大，部分资金选择获利了结。
今日CXO板块整体走弱，同行业康龙化成跌5.24%、药明合联跌5.11%、金斯瑞生物科技跌4.41%、药明康德跌1.05%，板块呈现集体回调态势。此前多家投行上调药明生物目标价（野村升至60.22港元、大摩升至57港元），基本面预期已充分反映，短期获利盘压力有所释放。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.